Home

The need for pure and highly specific antibodies in basic, applied and clinical research is obvious. The rapidly growing field of proteomics, along with the application of sensitive techniques in mass spectrometry, allows the identification and analysis of protein and peptide molecules at femtomolar concentrations. These low quantities of newly synthesized or specially modified proteins are often specific markers of disease. Their precise identification and quantification, mostly in quantities of a few molecules, will form a base for effective diagnostics, prevention, and treatment.

DB Biotech is introducing a new technology for the production of highly specific CLONAL antibodies. In vitro cloning technology developed by the company enables the preparation of a pure immunoglobulin fraction corresponding to a single clone of B lymphocytes. The obtained immunoglobulin recognizes one single linear epitope on the antigen molecule; therefore this antibody is comparable quality-wise to its monoclonal analogue. Moreover, the influence of the protein tertiary structure – frequently present in epitopes formed during production of monoclonal antibodies – is eliminated in immunoglobulins corresponding to the clonal antibody. In this case, the produced antibody corresponds strictly to the conserved linear epitope of the antigen molecule.